GO
Loading...

Enter multiple symbols separated by commas

Johnson & Johnson

More

  • JNJ expects 10 new drug filings by 2019   Wednesday, 20 May 2015 | 7:30 AM ET
    JNJ expects 10 new drug filings by 2019

    CNBC's Meg Tirrell has the update on JNJ's new drugs announcement, which has a $1 billion potential for each new drug.

  • May 19- Achillion Pharmaceuticals Inc said it will collaborate with Johnson& Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time. Johnson& Johnson will also invest $225 million in Achillion in return for about 18.4 million unregistered shares at $12.25 per share.

  • Achillion partners with J&J to develop hep C drugs Tuesday, 19 May 2015 | 4:29 PM ET

    May 19- Achillion Pharmaceuticals Inc said it will collaborate with Johnson& Johnson to develop and market one or more of its hepatitis C drugs. Achillion will be eligible for milestone payments of up to $1.1 billion related to the development, regulatory approval and sales of the drugs. Johnson& Johnson will also invest $225 million in Achillion in return for...

  • May 19- The U.S. Food and Drug Administration approved a longer-acting version of Johnson& Johnson's schizophrenia treatment, developed by the company's Janssen Pharmaceuticals unit. The FDA approved the drug, Invega Trinza, to be administered just four times a year, the longest dosing interval available for the treatment of the neurological disorder,...

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed higher, with the Dow and S&P setting records, as investors shook off concerns about Greek debt and a renewed rise in bond yields.

  • FDA warns on newer class of diabetes drugs Friday, 15 May 2015 | 11:53 AM ET
    Drug capsules and glass of water

    The agency warned that certain type 2 diabetes drugs may cause high levels of blood acid that could require hospitalization.

  • May 15- The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drugs sold by AstraZeneca, Johnson& Johnson and Eli Lilly in partnership with Boehringer Ingleheim may cause dangerously high levels of blood acids that could require hospitalization. The FDA said its Adverse Event Reporting System database...

  • U.S. FDA warns on newer class of type 2 diabetes drugs Friday, 15 May 2015 | 11:06 AM ET

    May 15- The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drug sold by AstraZeneca, Johnson& Johnson and Eli Lilly in partnership with Boehringer Ingleheim may a cause dangerously high levels of blood acids that could require hospitalization. They include AstraZeneca's Farxiga, J&J's Invokana and...

  • SALT LAKE CITY— A federal appeals court has halted a new Utah law banning price-fixing for contact lenses that could have wide-ranging implications for the industry amid a fight between manufacturers and discount retailers. Along with Johnson& Johnson and Bausch& Lomb, the company says the law is an unconstitutional overreach written to benefit Utah- based...

  • 500,000 Americans spend $50K on medicine each year Wednesday, 13 May 2015 | 12:01 AM ET
    Prescription drugs

    More than half a million Americans have annual prescription drug costs of more than $50,000.

  • May 8- A U.S. judge on Friday dismissed a lawsuit filed by the city of Chicago in federal court against four drugmakers accused of promoting painkiller addiction through deceptive marketing, though the case will continue against Oxycontin maker Purdue Pharma LP. The companies dismissed from the lawsuit are Teva Pharmaceutical Industries Ltd, Johnson&...

  • The right to try test drugs gets more transparent Thursday, 7 May 2015 | 3:57 PM ET
    An employee processes solutions containing samples taken from hazard suits and clothing to detect evidence of contamination in a laboratory at the Bavarian Nordic A/S biotechnology company.

    A development in how patient requests for experimental drugs are handled could be a big step in health care, said a medical director Thursday.

  • J&J opens door for more use of trial drugs Thursday, 7 May 2015 | 6:17 AM ET
    Arthur Caplan, Bioethicist

    Johnson & Johnson will become the first pharmaceutical company to formally seek advice from outside medical ethicists on "compassionate use" requests.

  • NEW YORK, May 7- Johnson& Johnson will become the first pharmaceutical company to formally seek advice from outside medical ethicists on "compassionate use" requests, in which desperate patients ask drugmakers to let them take an experimental medication, the company announced on Thursday. In 2013, doctors treating a 7- year-old with a potentially-fatal...

  • WASHINGTON, May 6- The U.S. Food and Drug Administration will hold a public meeting this summer to address drug company concern that restrictions on what they can say about off-label use of drugs violate their first amendment right to free speech. Efforts by drug companies to change the rules gained steam after a 2012 decision from the Second Circuit Court of...

  • INTERVIEW-New-look GSK bets on consumer health spending Wednesday, 6 May 2015 | 7:19 AM ET

    LONDON, May 6- Consumers from New York to New Delhi are digging deeper in their pockets for over-the-counter remedies and health products, a trend GlaxoSmithKline is banking on to help shape the next chapter in its evolution. In the biggest shake-up in its 15- year history, GSK has just sold its cancer drugs to Novartis, while buying the Swiss group's vaccine...

  • Dividend ETFs lose ground. Time to buy? Tuesday, 5 May 2015 | 2:10 PM ET
    Traders on the floor of the New York Stock Exchange.

    Why are dividend ETFs getting knocked as company after company raise their payouts?

  • Siemens unit in China bribery probe - report Sunday, 3 May 2015 | 5:42 AM ET
  • The investigation, which has not previously been reported, follows a wide-reaching probe into the pharmaceutical industry in China that last year saw GlaxoSmithKline Plc fined nearly $500 million for bribing officials to push its medicine sales. "We are not aware of any situation that conforms to what you describe," said Germany- based spokesman Matthias...

  • WASHINGTON, May 1- U.S. factory activity failed to gain steam in April after slowing for five straight months, but stronger-than-expected vehicle sales suggested the economy was finding some momentum after almost stalling in the first quarter. "The reacceleration in growth will not come fast enough for many, especially those looking for a liftoff by the Fed to...